CN101326179A - 新的嘧啶衍生物和它们在治疗中的用途及嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途 - Google Patents

新的嘧啶衍生物和它们在治疗中的用途及嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途 Download PDF

Info

Publication number
CN101326179A
CN101326179A CNA2006800454648A CN200680045464A CN101326179A CN 101326179 A CN101326179 A CN 101326179A CN A2006800454648 A CNA2006800454648 A CN A2006800454648A CN 200680045464 A CN200680045464 A CN 200680045464A CN 101326179 A CN101326179 A CN 101326179A
Authority
CN
China
Prior art keywords
alkyl
pyrimidine
imidazoles
fluoro
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800454648A
Other languages
English (en)
Chinese (zh)
Inventor
拉斯·安德森
欧万·阿泽尔
斯蒂芬·伯格
杰里米·伯罗斯
斯文·赫尔伯格
费尔南多·许尔塔
托本·佩德森
托拜厄斯·赖因
迪迪尔·罗蒂西
卡林·斯塔夫
多米尼卡·图雷克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101326179A publication Critical patent/CN101326179A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800454648A 2005-10-03 2006-10-02 新的嘧啶衍生物和它们在治疗中的用途及嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途 Pending CN101326179A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE05021746 2005-10-03
SE0502174 2005-10-03

Publications (1)

Publication Number Publication Date
CN101326179A true CN101326179A (zh) 2008-12-17

Family

ID=37906403

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800454648A Pending CN101326179A (zh) 2005-10-03 2006-10-02 新的嘧啶衍生物和它们在治疗中的用途及嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途

Country Status (20)

Country Link
US (1) US20090105252A1 (enExample)
EP (1) EP1945628A4 (enExample)
JP (1) JP2009513575A (enExample)
KR (1) KR20080059423A (enExample)
CN (1) CN101326179A (enExample)
AR (1) AR058073A1 (enExample)
AU (2) AU2006297890B2 (enExample)
BR (1) BRPI0616658A2 (enExample)
CA (1) CA2624875A1 (enExample)
EC (1) ECSP088405A (enExample)
IL (1) IL190150A0 (enExample)
NO (1) NO20082067L (enExample)
NZ (2) NZ566804A (enExample)
RU (2) RU2433128C2 (enExample)
SG (1) SG166125A1 (enExample)
TW (1) TW200800957A (enExample)
UA (1) UA92181C2 (enExample)
UY (1) UY29827A1 (enExample)
WO (1) WO2007040440A1 (enExample)
ZA (1) ZA200802897B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459252A (zh) * 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
CN102596917A (zh) * 2009-05-21 2012-07-18 阿斯利康(瑞典)有限公司 2-(4-((2-氨基-4-甲基-6-(戊基氨基)嘧啶-5-基)甲基)苯基)乙酸4-(二甲基氨基)丁酯的二糖精盐、二富马酸盐、二-(1-羟基-萘-2-甲酸)盐和单苯甲酸盐
CN114426542A (zh) * 2020-10-29 2022-05-03 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
CN115413278A (zh) * 2020-03-23 2022-11-29 丸仁制药株式会社 新型嘧啶衍生物以及包含其的神经退行性疾病和癌症的预防或治疗用组合物
CN116529252A (zh) * 2020-10-23 2023-08-01 重庆两江药物研发中心有限公司 用于持续释放治疗剂的前药及其用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
CA2729965A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
JP5640005B2 (ja) * 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
AP3272A (en) * 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
AU2010259035A1 (en) 2009-06-08 2011-12-08 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2016008966A1 (en) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
KR102342803B1 (ko) * 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
CN117915918A (zh) * 2021-04-28 2024-04-19 康奈尔大学 可溶性腺苷酸环化酶(sAC)抑制剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065979A2 (en) * 2001-02-20 2002-08-29 Astrazeneca Ab (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
WO2002066480A2 (en) * 2001-02-20 2002-08-29 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
WO2003037891A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2004056368A1 (en) * 2002-12-19 2004-07-08 Cyclacel Limited Therapeutic applications of 2-substituted 4-heteroarylryrimidines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530710A1 (de) 1985-08-28 1987-03-05 Hoechst Ag Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) * 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
JP2006518381A (ja) * 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
CA2522176A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005012298A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7132651B2 (en) 2004-04-23 2006-11-07 Framatome Anp, Inc. In-situ BWR and PWR CRUD flake analysis method and tool
AU2006274733B2 (en) * 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
WO2010120237A1 (en) * 2009-04-15 2010-10-21 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065979A2 (en) * 2001-02-20 2002-08-29 Astrazeneca Ab (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
WO2002066480A2 (en) * 2001-02-20 2002-08-29 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
WO2003037891A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2004056368A1 (en) * 2002-12-19 2004-07-08 Cyclacel Limited Therapeutic applications of 2-substituted 4-heteroarylryrimidines

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459252A (zh) * 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
CN102596917A (zh) * 2009-05-21 2012-07-18 阿斯利康(瑞典)有限公司 2-(4-((2-氨基-4-甲基-6-(戊基氨基)嘧啶-5-基)甲基)苯基)乙酸4-(二甲基氨基)丁酯的二糖精盐、二富马酸盐、二-(1-羟基-萘-2-甲酸)盐和单苯甲酸盐
CN102596917B (zh) * 2009-05-21 2015-01-21 阿斯利康(瑞典)有限公司 2-(4-((2-氨基-4-甲基-6-(戊基氨基)嘧啶-5-基)甲基)苯基)乙酸4-(二甲基氨基)丁酯的二糖精盐、二富马酸盐、二-(1-羟基-萘-2-甲酸)盐和单苯甲酸盐
CN115413278A (zh) * 2020-03-23 2022-11-29 丸仁制药株式会社 新型嘧啶衍生物以及包含其的神经退行性疾病和癌症的预防或治疗用组合物
CN115413278B (zh) * 2020-03-23 2025-01-10 丸仁制药株式会社 新型嘧啶衍生物以及包含其的神经退行性疾病和癌症的预防或治疗用组合物
CN116529252A (zh) * 2020-10-23 2023-08-01 重庆两江药物研发中心有限公司 用于持续释放治疗剂的前药及其用途
CN114426542A (zh) * 2020-10-29 2022-05-03 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
WO2022089497A1 (zh) * 2020-10-29 2022-05-05 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
TWI798905B (zh) * 2020-10-29 2023-04-11 大陸商蘇州亞寶藥物研發有限公司 取代的二芳基胺化合物及其藥物組合物、製備方法和用途

Also Published As

Publication number Publication date
US20090105252A1 (en) 2009-04-23
EP1945628A1 (en) 2008-07-23
NZ566804A (en) 2011-03-31
NZ591316A (en) 2012-06-29
CA2624875A1 (en) 2007-04-12
RU2433128C2 (ru) 2011-11-10
RU2008110910A (ru) 2009-11-10
UY29827A1 (es) 2007-05-31
EP1945628A4 (en) 2010-06-02
JP2009513575A (ja) 2009-04-02
ZA200802897B (en) 2008-12-31
KR20080059423A (ko) 2008-06-27
BRPI0616658A2 (pt) 2011-06-28
RU2011115406A (ru) 2012-10-27
SG166125A1 (en) 2010-11-29
IL190150A0 (en) 2008-08-07
ECSP088405A (es) 2008-05-30
AR058073A1 (es) 2008-01-23
UA92181C2 (ru) 2010-10-11
TW200800957A (en) 2008-01-01
WO2007040440A1 (en) 2007-04-12
AU2006297890A1 (en) 2007-04-12
AU2011200948A1 (en) 2011-03-24
AU2006297890B2 (en) 2011-04-28
NO20082067L (no) 2008-07-02

Similar Documents

Publication Publication Date Title
CN101326179A (zh) 新的嘧啶衍生物和它们在治疗中的用途及嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途
EP1492785B9 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
CN101426783B (zh) 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的环己基吡唑-内酰胺衍生物
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
WO2008002245A2 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
CN101511825A (zh) 用于治疗糖原合酶激酶（gsk3）相关疾病的咪唑-嘧啶衍生物
US7683067B2 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
WO2019034075A1 (zh) Fgfr和egfr抑制剂
EP1942897A1 (en) Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
JP2001233875A (ja) ピリミジン−５−カルボキサミド化合物、その製造法およびその用途
HK1126482A (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
CN103328446B (zh) 用于治疗癌症的新的4-氨基-n-羟基-苯甲酰胺
HK40048972A (en) Inhibitors of cyclin-dependent kinases
HK1071360B (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
HK1120512A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
HK1257578B (en) Heteroaryl compounds and their use as therapeutic drugs
JPWO2001027105A1 (ja) ピリミジン−５−カルボキサミド化合物、その製造法および用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126482

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126482

Country of ref document: HK